INTRODUCTION: To date, our knowledge on antihypertensive pharmacological treatment in children and adolescents is still limited because there are few randomized clinical trials (CTs), hampering appropriate management. The objective was to perform a narrative review of the most relevant aspects of clinical trials carried out in primary and secondary hypertension. METHODS: Studies published in PubMed with the following descriptors: clinical trial, antihypertensive drug, children, adolescents were selected. A previous Cochrane review of 21 randomized CTs pointed out the difficulty that statistical analysis could not assess heterogeneity because there were not enough data. A more recent meta-analysis, that applied more stringent inclusion criteria and selected 13 CTs, also concluded that heterogeneity, small sample size, and short follow-up time, as well as the absence of studies comparing drugs of different classes, limit the utility. RESULTS: In the presented narrative review, including 30 studies, there is a paucity of CTs focusing only on children with primary or secondary, mainly renoparenchymal, hypertension. In trials on angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics, a significant reduction of both SBP and DBP in mixed cohorts of children with primary and secondary hypertension was achieved. However, few studies assessed the effect of antihypertensive drugs on hypertensive organ damage. CONCLUSIONS: Given the increasing prevalence and undertreatment of hypertension in this age group, innovative solutions including new design, such as 'n-of-1', and optimizing the use of digital health technologies could provide more precise and faster information about the efficacy of each antihypertensive drug class and the potential benefits according to patient characteristics.

Department of Medical Clinical Pharmacology University of Debrecen Debrecen Hungary

Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark

Department of Pediatrics 2nd Faculty of Medicine Charles University Prague Prague Czechia

Division of Pediatric Nephrology Center for Pediatrics and Adolescent Medicine Heidelberg University Hospital Heidelberg Germany

Hypertension and Atherosclerosis Center Marmara University School of Medicine Istanbul Turkey

INCLIVA Research Institute CIBERObn Institute of Health Charles 3 University of Valencia Madrid Spain

Tallinn Children's Hospital Tallinn Estonia

University of Milano Bicocca Milan Italy

Zobrazit více v PubMed

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. (2013) 31:1281–357. 10.1097/01.hjh.0000431740.32696.cc PubMed DOI

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. (2018) 39:3021–104. 10.1093/eurheartj/ehy339 PubMed DOI

Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. . Management of high blood pressure in children and adolescents: recommendations of the European society of hypertension. J Hypertens. (2009) 27:1719–42. 10.1097/HJH.0b013e32832f4f6b PubMed DOI

Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. . 2016 European society of hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. (2016) 34:1887–920. 10.1097/HJH.0000000000001039 PubMed DOI

Drozdz D, Alvarez-Pitti J, Wójcik M, Borghi C, Gabbianelli R, Mazur A, et al. . Obesity and cardiometabolic risk factors: from childhood to adulthood. Nutrients. (2021) 13:4176. 10.3390/nu13114176 PubMed DOI PMC

Stabouli S, Kotsis V, Toumanidis S, Papamichael C, Constantopoulos A, Zakopoulos N. White-coat and masked hypertension in children: association with target-organ damage. Pediatr Nephrol. (2005) 20:1151–5. 10.1007/s00467-005-1979-5 PubMed DOI

Gupta-Malhotra M, Banker A, Shete S, Hashmi SS, Tyson JE, Barratt MS, et al. . Essential hypertension vs. secondary hypertension among children. Am J Hypertens. (2015) 28:73–80. 10.1093/ajh/hpu083 PubMed DOI PMC

Lurbe E, Litwin M, Pall D, Seeman T, Stabouli S, Webb NJA, et al. . Insights and implications of new blood pressure guidelines in children and adolescents. J Hypertens. (2018) 36:1456–9. 10.1097/HJH.0000000000001761 PubMed DOI

Páll D, Zrínyi M. Non-pharmacological treatment of hypertension. In: Lurbe E, Wühl E, editors. Hypertension in Children and Adolescents. Springer Nature Switzerland AG 2019. pp. 211–24. 10.1007/978-3-030-18167-3_13 DOI

Redon J, Redon P. Evidences from clinical trials and use of antihypertensive drugs in children and adolescents. In: Lurbe E, Wühl E, editors. Hypertension in children and adolescents. Springer Nature Switzerland AG 2019. p. 263–77. 10.1007/978-3-030-18167-3_17 DOI

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. 10.1136/bmj.n71 PubMed DOI PMC

Best Pharmaceuticals for Children Act and Pediatric Research Equity Act . Available online at https://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm509707.htm (accessed 11 June, 2022).

Food Drug Administration Safety Innovation Act (FDASIA) . Available online at https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/default.htm (accessed 11 June, 2022).

European Medicines Agency Addendum to the Guideline on Clinical Investigation of Medicinal Products in the Treatment of Hypertension (EMA/238/1995/Rev . 3, 18 November 2010 released in 26 February 2015. EMA/CHMP/206815/2013 Committee for Medicinal Products for Human Use (CHMP).

Faulkner B, Delgado-Charro MB. Cardiovascular paediatric medicines development: have paediatric investigation plans lost heart? Pharmaceutics. (2020) 12:1176. 10.3390/pharmaceutics12121176 PubMed DOI PMC

Paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension . (2015). Available online at: https://www.ema.europa.eu/en/paediatric-addendum-guideline-clinical-investigation-medicinal-products-treatment-hypertension

Principles for Clinical Evaluation of New Antihypertensive Drugs . (2000). Available online at: https://www.ema.europa.eu/en/ich-e12-principles-clinical-evaluation-new-antihypertensive-drugs-scientific-guideline

Geoffrey, Banks Why Do Clinical Trials Fail? Available online at: https://www.nuventra.com/resources/blog/why-do-clinical-trials-fail/

Hill PYC, li JS, Hornik CP. Pediatric trials of antihypertensive agents: impact of trial design and unique pediatric factors on efficacy end points. Clin Invest. (2014) 4:1031–41. 10.4155/cli.14.98 DOI

Seven Reasons Why Clinical Trials Fail. By Artem Andrianov . (2014). Available online at: https://cyntegrity.com/7-reasons-clinical-trials-fail/

Why Do Clinical Trials Fail? By Geoffrey Banks . (2018). Available online at: https://www.nuventra.com/resources/blog/ why-do-clinical-trials-fail/

Brewster R, Wong M, Magnani CJ, Gunningham H, Hoffer M, Showalter S, et al. . Early discontinuation, results reporting, and publication of pediatric clinical trials. Pediatrics. (2022) 149:e2021052557. 10.1542/peds.2021-052557 PubMed DOI

Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. (2014) 2:CD008117. 10.1002/14651858.CD008117.pub2 PubMed DOI PMC

Burrello J, Erhardt EM, Saint-Hilary G, Veglio F, Rabbia F, Mulatero P, et al. . Pharmacological treatment of arterial hypertension in children and adolescents: a network meta-analysis. Hypertension. (2018) 72:306–13. 10.1161/HYPERTENSIONAHA.118.10862 PubMed DOI

Falkner B, Onesti G, Lowenthal DT, Affrime MB. Use of clonidine monotherapy (versus diuretics) in adolescent hypertension. Chest. (1983) 83:425–7. 10.1378/chest.83.2.425 PubMed DOI

Bachmann H. Propranolol versus chlorthalidone—a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta. (1984) 39:55–61. PubMed

Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, et al. . The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. (2010) 157:282–7. 10.1016/j.jpeds.2010.02.042 PubMed DOI

Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. . Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebocontrolled trial. Pediatr Nephrol. (2002) 17:345–50. 10.1007/s00467-002-0851-0 PubMed DOI

Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. . Efficacy and safety of extended-release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. (2007) 150:134–9. 10.1016/j.jpeds.2006.09.034 PubMed DOI

Tabbutt S, Nicolson SC, Adamson PC, Zhang X, Hoffman ML, Wells W, et al. . The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg. (2008) 136:321–8. 10.1016/j.jtcvs.2007.09.086 PubMed DOI

Di Salvo G, Castaldi B, Gala S, Baldini L, Del Gaizo F, D'Aiello FA, et al. . Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation. J Hum Hypertens. (2016) 30:363–7. 10.1038/jhh.2015.87 PubMed DOI

Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G, et al. . randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. (2000) 14:1083–7. 10.1007/s004670000400 PubMed DOI

Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. . Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. (2003) 18:548–53. 10.1007/s00467-003-1134-0 PubMed DOI

Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. . A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. (2004) 145:353–9. 10.1016/j.jpeds.2004.04.009 PubMed DOI

Soergel M, Verho M, Wühl E, Gellermann J, Teichert L, Schärer K. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol. (2000) 15:113–8. 10.1007/s004670000422 PubMed DOI

Seeman T, Dusek J, Vondrák K, Flögelová H, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. Am J Hypertens. (2004) 17:415–20. 10.1016/j.amjhyper.2004.01.008 PubMed DOI

ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. . Strict blood-pressure control and progression of renal failure in children. N Engl J Med. (2009) 361:1639–50. 10.1056/NEJMoa0902066 PubMed DOI

Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. . A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. (2002) 42:870–80. 10.1177/009127002401102786 PubMed DOI

Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S, A. double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. (2003) 16:795–800. 10.1016/S0895-7061(03)00900-2 PubMed DOI

Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. . Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. (2004) 44:289–93. 10.1161/01.HYP.0000138069.68413.f0 PubMed DOI

Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, et al. . Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. (2011) 29:2484–90. 10.1097/HJH.0b013e32834c625c PubMed DOI

Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. . A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. (2005) 18:183–90. 10.1016/j.amjhyper.2004.09.009 PubMed DOI

Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al. . Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. (2008) 52:222–8. 10.1161/HYPERTENSIONAHA.108.111054 PubMed DOI

Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, et al. . Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens. (2008) 10:743–50. 10.1111/j.1751-7176.2008.00022.x PubMed DOI PMC

Wells TG, Portman R, Norman P, Haertter S, Davidai G, Wang F. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr. (2010) 49:938–46. 10.1177/0009922810363609 PubMed DOI

Hazan L, Hernández Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R, et al. . A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. (2010) 55:1323–30. 10.1161/HYPERTENSIONAHA.109.147702 PubMed DOI

Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. . Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. (2010) 28:1083–90. 10.1097/HJH.0b013e328336b86b PubMed DOI

Meyers KEC, Lieberman K, Solar-Yohay S, Han G, Shi V. The efficacy and safety of valsartan in obese and nonobese pediatric hypertensive patients. J Clin Hypertens. (2011) 13:758–66. 10.1111/j.1751-7176.2011.00502.x PubMed DOI PMC

Wells T, Blumer J, Meyers KE, Neto JP, Meneses R, Litwin M, et al. . Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens. (2011) 13:357–65. 10.1111/j.1751-7176.2011.00432.x PubMed DOI PMC

Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, et al. . Efficacy and safety of losartan in children with Alport syndrome–results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. (2011) 26:2521–6. 10.1093/ndt/gfq797 PubMed DOI

Schaefer F, Coppo R, Bagga A, Senguttuvan P, Schlosshauer R, Zhang Y, et al. . Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens. (2013) 31:993–1000. 10.1097/HJH.0b013e32835f5721 PubMed DOI

Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al. . A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol. (2014) 9:1441–8. 10.2215/CJN.11111113 PubMed DOI PMC

Lou-Meda R, Stiller B, Antonio ZL, Zielinska E, Yap HK, Kang HG, et al. . Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension. Pediatr Nephrol. (2019) 34:495–506. 10.1007/s00467-018-4114-0 PubMed DOI PMC

Jankauskiene A, Drozdz D, Wasilewska A, de Paula-Bernardes R, Glazer R, Valentin M, et al. . Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase. Curr Med Res Opin. (2021) 37:2113–22. 10.1080/03007995.2021.1982681 PubMed DOI

Ito S, Nishiyama Y, Sugiura K, Enya K. Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study. Clin Exp Nephrol. (2022) 26:350–8. 10.1007/s10157-021-02159-9 PubMed DOI PMC

ClinicalTrials.gov . Search Results (accessed May 07, 2022).

Kravitz RL, Duan N. eds the DEcIDE Methods Center N-of-1 Guidance Panel. Design and Implementation of N-of-1 Trials: A User's Guide. AHRQ Publication No. 13(14)-EHC122-EF. Rockville, MD: Agency for Healthcare Research and Quality; (2014).

Samuel JP, Tyson JE, Green C, Bell CS, Pedroza C, Molony D, et al. . Treating hypertension in children with n-of-1 trials. Pediatrics. (2019) 143:e20181818. 10.1542/peds.2018-1818 PubMed DOI PMC

Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, et al. . Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper. Hypertension. (2020) 76:1368–83. 10.1161/HYPERTENSIONAHA.120.15873 PubMed DOI

Aydemir S, Ocak S, Saygili S, Hopurcuoglu D, Haşlak F, Kiykim E, et al. . Telemedicine applications in a tertiary pediatric hospital in turkey during COVID-19 pandemic. Telemed J E Health. (2021) 27:1180–7. 10.1089/tmj.2020.0381 PubMed DOI

Omboni S, Caserini M, Coronetti C. Telemedicine and M-Health in hypertension management: technologies, applications and clinical evidence. High Blood Press Cardiovasc Prev. (2016) 23:187–96. 10.1007/s40292-016-0143-6 PubMed DOI

Purcell R, McInnes S, Halcomb EJ. Telemonitoring can assist in managing cardiovascular disease in primary care: a systematic review of systematic reviews. BMC Fam Pract. (2014) 15:43. 10.1186/1471-2296-15-43 PubMed DOI PMC

Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. (2017) 69:2657–64. 10.1016/j.jacc.2017.03.571 PubMed DOI

Bzdok D, Altman N, Krzywinski M. Statistics versus machine learning. Nat Methods. (2018) 15:233–4. 10.1038/nmeth.4642 PubMed DOI PMC

Bzdok D, Krzywinski M, Altman N. Points of significance: machine learning: a primer. Nat Methods. (2017) 14:1119–20. 10.1038/nmeth.4526 PubMed DOI PMC

Niel O, Bastard P, Boussard C, Hogan J, Kwon T, Deschênes G. Artificial intelligence outperforms experienced nephrologists to assess dry weight in pediatric patients on chronic hemodialysis. Pediatr Nephrol. (2018) 33:1799–803. 10.1007/s00467-018-4015-2 PubMed DOI

Padmanabhan S, Tran TQB, Dominiczak AF. Artificial intelligence in hypertension: seeing through a glass darkly. Circ Res. (2021) 128:1100–18. 10.1161/CIRCRESAHA.121.318106 PubMed DOI